Skip to main content
. 2024 Jan 9;119(2):146–155. doi: 10.1007/s12185-023-03687-8

Fig. 3.

Fig. 3

Adverse events (other than mantle cell lymphoma progression and death) occurring in ≥ 3% of patients. WBC white blood cell